1 |
ION363 (ulefnersen) |
3
|
- antisense oligonucleotide treatment for people carrying a mutation in FUS gene
- recruiting in CA, MD, MA, MO, NY, OH, UT
|
IONIS
|
2
|
Masitinib |
3
|
- 33% chance of placebo
- trial volunteers will be separated into 3 groups, a high dose with riluzole, a low dose with riluzole, or placebo with riluzole
- recruiting in AL, CA, KY, MD, MA, VA
|
AB Sciences
|
3 |
Tofersen - ATLAS (for presymptomatic SOD1) |
3
|
- biomarkers will be monitored over time and tofersen or placebo will be administered if specific biomarker changes occur
- antisense oligonucleotide treatment for people carrying specific SOD1 mutations, but no current symptoms of ALS
- recruiting in AZ, CA, FL, GA, IL, MD, MA, MO, NY, TX
|
Biogen
|
4 | ABBV-CLS-7262 Regimen F Healey Platform Trial | 2/3 | - 25% chance of placebo for 6 months followed by active treatment extension for all participants
- 2 doses are being tested
- recruiting in AZ, AR, CA, CO, CT, DC, FL, GA, ID, IL, IN, IA, KS, KY, MD, MA, MI, MN, MO, NE, NH, NJ, NY, NC, OH, OR, PA, TN, TX, UT, VA, WA, WI
| Merit Cudkowicz, MD |
5 | DNL 343 Regimen G Healey Platform Trial | 2/3 | - 25% chance of placebo for 6 months followed by active treatment extension for all participants
- single dose is being tested
- recruiting in AZ, AR, CA, CO, CT, DC, FL, GA, ID, IL, IN, IA, KS, KY, MD, MA, MI, MN, MO, NE, NH, NJ, NY, NC, OH, OR, PA, TN, TX, UT, VA, WA, WI
| Merit Cudkowicz, MD
|
6 |
Ibudilast |
2/3
|
- 50% chance of placebo for 12 months followed by an open label extension for 6 months
- recruiting in CA, FL, GA, IN, KS, MD, MN, NY, NC, OR, PA, VA
|
MediciNova
|
7 | Rapa-501 | 2/3 | - no placebo
-
autologous T cells are administered intravenously for 6 months followed by an additional 6 months of observation
- recruiting in MA, NJ
| Rapa Therapeutics |
8 |
AP-101 |
2
|
- placebo-controlled trial
- drug is delivered intravenously
- trial is for people carrying SOD1 mutation or sporadic ALS
- recruiting in CA
|
AL-S Pharma
|
9 |
BLZ945 |
2
|
- no placebo
- multiple groups or “cohorts” with cohorts 1-4 all receiving treatment and PET imaging, while in cohort 5 participants will be split into two groups that will either receive PET imaging or contribute to spinal fluid analysis
- recruiting in CA, CT, MA
|
Novartis
|
10 | | 2 | - 33% chance of placebo, 2 doses being tested
- 24 weeks trial followed by weeks of open label extension
- recruiting in AZ, CA, NJ, NY
| Corcept Therapeutics |
11 |
PTC857 |
2
|
- 50% chance of placebo for 24 weeks followed by 28 weeks of open label extension
- recruiting in CA, FL, GA, NE, TX, WI
|
PTC Therapeutics
|
12 |
Vitamin E, N-acetyl cysteine, L-cystine, nicotinamide, and taurursodiol |
2
|
-
no placebo
- recruiting in TX
|
Dallas VA Medical Center
|
13 |
Istradefylline and AIH |
1/2
|
-
crossover study: all trial volunteers will receive placebo and all trial volunteers will receive active treatment at different timepoints
- recruiting in FL
|
University of Florida
|
14 |
baricitinib |
1
|
-
no placebo
- includes people living with different neurodegenerative diseases including ALS
- recruiting in MA
|
Massachusetts General Hospital
|
15 | | 1 | - placebo controlled trial
- umbilical cord derived T regulatory cells delivered intravenously
- recruiting in NY, TX
| Cellenkos |
16 |
CNS10-NPC-GDNF |
1
|
-
no placebo
- cells that produce GDNF (a growth factor) will be transplanted into motor cortex of brain
- recruiting in CA
|
Cedars-Sinai Medical Center
|
17 | CNM-Au8 | EAP | - Expanded Access Program for people that are not eligible for trials
- CNM-Au8 will be administered for up to 96 weeks orally or by feeding tube
- sites in AZ, CA, CT, FL, IL, KS, MI, NE, NC, OR, PA, TX,
| Clene Nanomedicine |
18 | SLS-005 (trehalose) | EAP | - Expanded Access Program for people that are not eligible for trials
- trehalose is delivered by 25 intravenous infusions over 24 weeks
- sites in AZ, CA, CO, CT, FL, ID, IN, IA, MA, MN, MO, NY, PA, TX, VA
| Seelos Therapeutics, Inc. |
19 | Rapa 501 | EAP | - Expanded Access Program for people that are not eligible for trials
- Autologous hybrid TREG/Th2 cells delivered intravenously
- sites in MA, NJ
| Rapa Therapeutics
|
20 | pridopidine | EAP | - Expanded Access Program for people that are not eligible for trials
- pridopidine will be administered twice daily by mouth or feeding tube for 2 years
- sites not yet listed, but contact information is available on clinicaltrials.gov
| Prilenia |